Lilly’s generic rapid-acting insulin hits pharmacy shelves

Eli Lilly’s cheaper, generic insulin lispro injection offering can now be ordered in pharmacies, according to a press release from the company.

"The current health care system isn't working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine," Mike Mason, senior vice president of Connected Care and Insulins at Eli Lilly, said in the release. "But even one person with diabetes who can't afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved."

As Endocrine Today previously reported, the authorized generic insulin lispro is meant to reduce insulin costs by 50% for customers who opt to switch from Humalog U-100 (Lilly) even though the two are the same insulin, according to the company. Those with diabetes will be able to acquire the insulin lispro injection either on a per vial basis for $137.35 or as a package of five pens for $265.20 based on list prices, although the company noted that out-of-pocket costs can be lower depending on a person’s health insurance coverage.

"The availability of Lilly's Insulin Lispro Injection is important progress that helps more people afford their insulin," Mason said in the release. "Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines."

Eli Lilly’s cheaper, generic insulin lispro injection offering can now be ordered in pharmacies, according to a press release from the company.

"The current health care system isn't working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine," Mike Mason, senior vice president of Connected Care and Insulins at Eli Lilly, said in the release. "But even one person with diabetes who can't afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved."

As Endocrine Today previously reported, the authorized generic insulin lispro is meant to reduce insulin costs by 50% for customers who opt to switch from Humalog U-100 (Lilly) even though the two are the same insulin, according to the company. Those with diabetes will be able to acquire the insulin lispro injection either on a per vial basis for $137.35 or as a package of five pens for $265.20 based on list prices, although the company noted that out-of-pocket costs can be lower depending on a person’s health insurance coverage.

"The availability of Lilly's Insulin Lispro Injection is important progress that helps more people afford their insulin," Mason said in the release. "Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines."